Targeting regulatory T cells in tumors

FEBS Journal

Volumn , Issue , 2016, Pages 2731-2748

  Liu, Chang ^a   Workman, Creg J ^a   Vignali, Dario A A ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

cancer immunotherapy; immune contexture; immunosuppression; regulatory T cells; tumor microenvironment

Indexed keywords

5' NUCLEOTIDASE; B7 ANTIGEN; CD39 ANTIGEN; CD45RA ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HERMES ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 35; INTERLEUKIN 7 RECEPTOR; L SELECTIN; MACROPHAGE DERIVED CHEMOKINE; OSTEOCLAST DIFFERENTIATION FACTOR; RANTES; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPORT; CYTOLYSIS; DOWN REGULATION; ENZYME REPRESSION; GENE MUTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84978933843     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13656     Document Type: Review

References (141)

1. Hanahan D & Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646–674.
2. Hanahan D & Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322.
3. Joyce JA & Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9, 239–252.
4. Fridman WH, Pages F, Sautes-Fridman C & Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12, 298–306.
5. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P et al. (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27, 5944–5951.
6. Fontenot JD, Gavin MA & Rudensky AY (2003) Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells. Nat Immunol 4, 330–336.
7. Hori S, Nomura T & Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057–1061.
8. Vignali DA, Collison LW & Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8, 523–532.
9. Ramsdell F & Ziegler SF (2014) FOXP3 and scurfy: how it all began. Nat Rev Immunol 14, 343–349.
10. Arpaia N, Green JA, Moltedo B, Arvey A, Hemmers S, Yuan S, Treuting PM & Rudensky AY (2015) A distinct function of regulatory T cells in tissue protection. Cell 162, 1078–1089.
11. Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, Zheng Y, Umetsu DT & Rudensky AY (2012) Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 482, 395–399.
12. Samstein RM, Josefowicz SZ, Arvey A, Treuting PM & Rudensky AY (2012) Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell 150, 29–38.
13. Darrasse-Jeze G & Podsypanina K (2013) How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development. Front Immunol 4, 292.
14. Bilate AM & Lafaille JJ (2012) Induced CD4 + Foxp3 + regulatory T cells in immune tolerance. Annu Rev Immunol 30, 733–758.
15. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10, 942–949.
16. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA & Dirnhofer S (2008) Correlation of high numbers of intratumoral FOXP3 + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 93, 193–200.
17. Vignali DA (2013) Interview: immunotherapeutic manipulation of the tumor microenvironment. Immunotherapy 5, 1279–1281.
18. Feuerer M, Hill JA, Mathis D & Benoist C (2009) Foxp3 + regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 10, 689–695.
19. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, de St Fazekas et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 + T reg cells. J Exp Med 203, 1701–1711.
20. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D et al. (2009) Functional delineation and differentiation dynamics of human CD4 + T cells expressing the FoxP3 transcription factor. Immunity 30, 899–911.
21. Wang C, Lee JH & Kim CH (2012) Optimal population of FoxP3 + T cells in tumors requires an antigen priming-dependent trafficking receptor switch. PLoS One 7, e30793.
22. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D et al. (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69, 2000–2009.
23. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell'Acqua ML et al. (2007) Expression of ectonucleotidase CD39 by Foxp3 + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110, 1225–1232.
24. Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X & Lu B (2012) TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 7, e30676.
25. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS & Linehan DC (2009) Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 182, 1746–1755.
26. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM & Karin M (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470, 548–553.
27. Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE, Bettini ML, Vogel P, Finkelstein D, Bonnevier J et al. (2013) Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501, 252–256.
28. Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T & Smyth MJ (2010) Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res 70, 7800–7809.
29. Teng MW, Swann JB, von Scheidt B, Sharkey J, Zerafa N, McLaughlin N, Yamaguchi T, Sakaguchi S, Darcy PK & Smyth MJ (2010) Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res 70, 2665–2674.
30. Li X, Kostareli E, Suffner J, Garbi N & Hammerling GJ (2010) Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur J Immunol 40, 3325–3335.
31. Bos PD, Plitas G, Rudra D, Lee SY & Rudensky AY (2013) Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med 210, 2435–2466.
32. Roeser JC, Leach SD & McAllister F (2015) Emerging strategies for cancer immunoprevention. Oncogene 34, 6029–6039.
33. DeNardo DG, Andreu P & Coussens LM (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 29, 309–316.
34. Pommier A, Audemard A, Durand A, Lengagne R, Delpoux A, Martin B, Douguet L, Le Campion A, Kato M, Avril MF et al. (2013) Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4 + T cells. Proc Natl Acad Sci USA 110, 13085–13090.
35. Fujimura T, Ring S, Umansky V, Mahnke K & Enk AH (2012) Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol 132, 1239–1246.
36. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S & Taams LS (2007) CD4 + CD25 + Foxp3 + regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 104, 19446–19451.
37. Giatromanolaki A, Bates GJ, Koukourakis MI, Sivridis E, Gatter KC, Harris AL & Banham AH (2008) The presence of tumor-infiltrating FOXP3 + lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol 110, 216–221.
38. Gupta S, Joshi K, Wig JD & Arora SK (2007) Intratumoral FOXP3 expression in infiltrating breast carcinoma: its association with clinicopathologic parameters and angiogenesis. Acta Oncol 46, 792–797.
39. Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA et al. (2008) TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13, 507–518.
40. Qin Z & Blankenstein T (2000) CD4 + T cell–mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12, 677–686.
41. Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borras-Cuesta F & Lasarte JJ (2003) CD4 +/CD25 + regulatory cells inhibit activation of tumor-primed CD4 + T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171, 5931–5939.
42. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P & Hammerling GJ (2015) Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol 16, 609–617.
43. Mougiakakos D, Choudhury A, Lladser A, Kiessling R & Johansson CC (2010) Regulatory T cells in cancer. Adv Cancer Res 107, 57–117.
44. Mailloux AW & Young MR (2010) Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit Rev Immunol 30, 435–447.
45. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L & Pisa P (2006) CD4 + CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177, 7398–7405.
46. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H & Fujii H (2008) CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3 + regulatory T cells in gastric cancer. Int J Cancer 122, 2286–2293.
47. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H & Ueda R (2006) Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 66, 5716–5722.
48. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E et al. (2011) A CCR4 antagonist combined with vaccines induces antigen-specific CD8 + T cells and tumor immunity against self antigens. Blood 118, 4853–4862.
49. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H et al. (2012) Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 30, 837–842.
50. Yan M, Jene N, Byrne D, Millar EK, O'Toole SA, McNeil CM, Bates GJ, Harris AL, Banham AH, Sutherland RL et al. (2011) Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res 13, R47.
51. Wald O, Izhar U, Amir G, Avniel S, Bar-Shavit Y, Wald H, Weiss ID, Galun E & Peled A (2006) CD4 + CXCR4highCD69 + T cells accumulate in lung adenocarcinoma. J Immunol 177, 6983–6990.
52. Jaafar F, Righi E, Lindstrom V, Linton C, Nohadani M, Van Noorden S, Lloyd T, Poznansky J, Stamp G, Dina R et al. (2009) Correlation of CXCL12 expression and FoxP3 + cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am J Pathol 175, 1525–1535.
53. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D et al. (2011) CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 71, 5522–5534.
54. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L et al. (2011) Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475, 226–230.
55. Hansen W, Hutzler M, Abel S, Alter C, Stockmann C, Kliche S, Albert J, Sparwasser T, Sakaguchi S, Westendorf AM et al. (2012) Neuropilin 1 deficiency on CD4 + Foxp3 + regulatory T cells impairs mouse melanoma growth. J Exp Med 209, 2001–2016.
56. Darrasse-Jeze G, Bergot AS, Durgeau A, Billiard F, Salomon BL, Cohen JL, Bellier B, Podsypanina K & Klatzmann D (2009) Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Investig 119, 2648–2662.
57. Malchow S, Leventhal DS, Nishi S, Fischer BI, Shen L, Paner GP, Amit AS, Kang C, Geddes JE, Allison JP et al. (2013) Aire-dependent thymic development of tumor-associated regulatory T cells. Science 339, 1219–1224.
58. Darrasse-Jeze G, Deroubaix S, Mouquet H, Victora GD, Eisenreich T, Yao KH, Masilamani RF, Dustin ML, Rudensky A, Liu K et al. (2009) Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med 206, 1853–1862.
59. Pandiyan P, Zheng L, Ishihara S, Reed J & Lenardo MJ (2007) CD4 + CD25 + Foxp3 + regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4 + T cells. Nat Immunol 8, 1353–1362.
60. Szymczak-Workman AL, Delgoffe GM, Green DR & Vignali DA (2011) Cutting edge: regulatory T cells do not mediate suppression via programmed cell death pathways. J Immunol 187, 4416–4420.
61. Ahmadzadeh M & Rosenberg SA (2006) IL-2 administration increases CD4 + CD25(hi) Foxp3 + regulatory T cells in cancer patients. Blood 107, 2409–2414.
62. Jensen HK, Donskov F, Nordsmark M, Marcussen N & von der Maase H (2009) Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res 15, 1052–1058.
63. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G & Rivoltini L (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25, 2546–2553.
64. Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, Kroemer G, Martin F, Chauffert B & Zitvogel L (2005) Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4 + CD25 + regulatory T cell proliferation. J Exp Med 202, 919–929.
65. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H & Strober W (2004) TGF-beta 1 plays an important role in the mechanism of CD4 + CD25 + regulatory T cell activity in both humans and mice. J Immunol 172, 834–842.
66. Munn DH & Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34, 137–143.
67. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL & Munn DH (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Investig 117, 2570–2582.
68. Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munn DH & Young JW (2009) Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 114, 555–563.
69. Lob S, Konigsrainer A, Rammensee HG, Opelz G & Terness P (2009) Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 9, 445–452.
70. Nishikawa H & Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127, 759–767.
71. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT & Whiteside TL (2007) A unique subset of CD4 + CD25highFoxp3 + T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13, 4345–4354.
72. Sawant DV, Hamilton K & Vignali DA (2015) Interleukin-35: expanding its job profile. J Interferon Cytokine Res 35, 499–512.
73. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS & Vignali DA (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566–569.
74. Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ & McNeel DG (2012) Human prostate tumor antigen-specific CD8 + regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol 189, 5590–5601.
75. Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, Basu S, Feng Y & Bai XF (2013) Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol 190, 2415–2423.
76. Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ & Vignali DAA (2016) Interleukin-35 limits anti-tumor immunity. Immunity 44, 316–319.
77. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR & Ley TJ (2007) Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27, 635–646.
78. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T & Sakaguchi S (2008) CTLA-4 control over Foxp3 + regulatory T cell function. Science 322, 271–275.
79. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z et al. (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332, 600–603.
80. Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, Flores M, Li N, Schweighoffer E, Greenberg S et al. (2008) Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180, 5916–5926.
81. Sage PT, Francisco LM, Carman CV & Sharpe AH (2013) The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol 14, 152–161.
82. Paterson AM, Lovitch SB, Sage PT, Juneja VR, Lee Y, Trombley JD, Arancibia-Carcamo CV, Sobel RA, Rudensky AY, Kuchroo VK et al. (2015) Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J Exp Med 212, 1603–1621.
83. Kumanogoh A, Marukawa S, Suzuki K, Takegahara N, Watanabe C, Ch'ng E, Ishida I, Fujimura H, Sakoda S, Yoshida K et al. (2002) Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature 419, 629–633.
84. Kumanogoh A, Shikina T, Suzuki K, Uematsu S, Yukawa K, Kashiwamura S, Tsutsui H, Yamamoto M, Takamatsu H, Ko-Mitamura EP et al. (2005) Nonredundant roles of Sema4A in the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice. Immunity 22, 305–316.
85. Sarris M, Andersen KG, Randow F, Mayr L & Betz AG (2008) Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 28, 402–413.
86. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C et al. (2014) Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 232, 199–209.
87. Angell H & Galon J (2013) From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 25, 261–267.
88. Sasaki A, Tanaka F, Mimori K, Inoue H, Kai S, Shibata K, Ohta M, Kitano S & Mori M (2008) Prognostic value of tumor-infiltrating FOXP3 + regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 34, 173–179.
89. Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K & Ueoka H (2012) Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 75, 95–101.
90. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH et al. (2006) Prognostic value of tumor-infiltrating CD4 + T-cell subpopulations in head and neck cancers. Clin Cancer Res 12, 465–472.
91. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, Oertli D, Kettelhack C, Terracciano L & Tornillo L (2010) High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 126, 2635–2643.
92. deLeeuw RJ, Kost SE, Kakal JA & Nelson BH (2012) The prognostic value of FoxP3 + tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18, 3022–3029.
93. Whiteside TL (2015) The role of regulatory T cells in cancer immunology. Immunotargets Ther 2015, 159–171.
94. Watanabe Y, Katou F, Ohtani H, Nakayama T, Yoshie O & Hashimoto K (2010) Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109, 744–752.
95. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C et al. (2005) Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102, 18538–18543.
96. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW & Tang ZY (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25, 2586–2593.
97. Scharovsky OG, Mainetti LE & Rozados VR (2009) Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 16, 7–15.
98. Galluzzi L, Senovilla L, Zitvogel L & Kroemer G (2012) The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discovery 11, 215–233.
99. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A et al. (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 61, 353–362.
100. Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, Weinberg AD, Wolchok JD & Houghton AN (2009) OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 206, 1103–1116.
101. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ & Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58, 49–59.
102. Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, Medioni J, Peyrard S, Roncelin S, Verkarre V et al. (2010) A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 33, 991–998.
103. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R et al. (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14, 6674–6682.
104. Desar IM, Jacobs JH, Hulsbergen-vandeKaa CA, Oyen WJ, Mulders PF, van der Graaf WT, Adema GJ, van Herpen CM & de Vries IJ (2011) Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer 129, 507–512.
105. Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, Lundeen T, Bonnotte B & Katsanis E (2008) Imatinib mesylate inhibits CD4 + CD25 + regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol 181, 6955–6963.
106. Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd et al. (2012) A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One 7, e31046.
107. Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH et al. (2012) CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 4, 134ra62.
108. Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, Klasen IS, Hilbrands LB, Figdor CG, de Vries IJ et al. (2010) Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res 16, 5067–5078.
109. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E et al. (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Investig 115, 3623–3633.
110. Attia P, Maker AV, Haworth LR, Rogers-Freezer L & Rosenberg SA (2005) Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28, 582–592.
111. Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y & Duvic M (2006) CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 126, 575–583.
112. Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y et al. (2013) Anti-CCR4 mAb selectively depletes effector-type FoxP3 + CD4 + regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA 110, 17945–17950.
113. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD et al. (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210, 1695–1710.
114. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C & Sharma P (2008) CTLA-4 blockade increases IFNgamma-producing CD4 + ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 105, 14987–14992.
115. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M & Korman AJ (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1, 32–42.
116. Shimizu J, Yamazaki S, Takahashi T, Ishida Y & Sakaguchi S (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3, 135–142.
117. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T & Sakaguchi S (2005) Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3 + CD25 + CD4 + regulatory T cells. J Exp Med 202, 885–891.
118. Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ et al. (2010) Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 16, 2781–2791.
119. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD & Colombo MP (2005) Triggering of OX40 (CD134) on CD4(+)CD25 + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105, 2845–2851.
120. Piconese S, Valzasina B & Colombo MP (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205, 825–839.
121. Lesokhin AM, Callahan MK, Postow MA & Wolchok JD (2015) On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med 7, 280sr1.
122. Chaudhary B, Khaled YS, Ammori BJ & Elkord E (2014) Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother 63, 81–99.
123. Graziani G & Lacal PM (2015) Neuropilin-1 as therapeutic target for malignant melanoma. Front Oncol 5, 125.
124. Greten TF, Ormandy LA, Fikuart A, Hochst B, Henschen S, Horning M, Manns MP & Korangy F (2010) Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4 + T-cell responses in patients with advanced HCC. J Immunother 33, 211–218.
125. Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A & Zheng SS (2011) Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 6, e24671.
126. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y et al. (2012) TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 22, 291–303.
127. Liu Q, Rexiati M, Yang Y, Wang WG, Azhati B, Saimaiti W & Wang YJ (2014) Expression of chemokine receptor 4 was associated with poor survival in renal cell carcinoma. Med Oncol 31, 882.
128. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S et al. (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30, 825–830.
129. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R et al. (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18, 1254–1261.
130. Miracco C, Mourmouras V, Biagioli M, Rubegni P, Mannucci S, Monciatti I, Cosci E, Tosi P & Luzi P (2007) Utility of tumour-infiltrating CD25 + FOXP3 + regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep 18, 1115–1122.
131. Ladanyi A, Mohos A, Somlai B, Liszkay G, Gilde K, Fejos Z, Gaudi I & Timar J (2010) FOXP3 + cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma. Pathol Oncol Res 16, 303–309.
132. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO & Green AR (2011) An evaluation of the clinical significance of FOXP3 + infiltrating cells in human breast cancer. Breast Cancer Res Treat 127, 99–108.
133. Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F et al. (2011) Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 125, 65–72.
134. Rech AJ & Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174, 99–106.
135. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH & Nelson BH (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4, e6412.
136. Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B et al. (2007) Interleukin-2 administration alters the CD4 + FOXP3 + T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 67, 7487–7494.
137. Drennan S, Stafford ND, Greenman J & Green VL (2013) Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement. Immunology 140, 335–343.
138. Schott AK, Pries R & Wollenberg B (2010) Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. Int J Mol Med 26, 67–75.
139. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS & Niedobitek G (2009) Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 27, 31–39.
140. Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R et al. (2009) Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 15, 6446–6453.
141. Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, Kang CW, Peng HM, Chu YY, Chiang JM, Dutta A et al. (2012) Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res 72, 1092–1102.